257 related articles for article (PubMed ID: 18767898)
1. Exploring uncertainty in cost-effectiveness analysis.
Claxton K
Pharmacoeconomics; 2008; 26(9):781-98. PubMed ID: 18767898
[TBL] [Abstract][Full Text] [Related]
2. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?
Sculpher M; Claxton K
Value Health; 2005; 8(4):433-46. PubMed ID: 16091019
[TBL] [Abstract][Full Text] [Related]
3. Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making.
Andronis L; Barton P; Bryan S
Health Technol Assess; 2009 Jun; 13(29):iii, ix-xi, 1-61. PubMed ID: 19500484
[TBL] [Abstract][Full Text] [Related]
4. Procedures and methods of benefit assessments for medicines in Germany.
Bekkering GE; Kleijnen J
Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
[TBL] [Abstract][Full Text] [Related]
5. Neuropsychotherapeutics in the UK: what has been the impact of NICE on prescribing?
Walley T
CNS Drugs; 2004; 18(1):1-12. PubMed ID: 14731055
[TBL] [Abstract][Full Text] [Related]
6. The use of economic evaluations in NHS decision-making: a review and empirical investigation.
Williams I; McIver S; Moore D; Bryan S
Health Technol Assess; 2008 Apr; 12(7):iii, ix-x, 1-175. PubMed ID: 18373906
[TBL] [Abstract][Full Text] [Related]
7. Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra.
Claxton K; Sculpher M; McCabe C; Briggs A; Akehurst R; Buxton M; Brazier J; O'Hagan T
Health Econ; 2005 Apr; 14(4):339-47. PubMed ID: 15736142
[TBL] [Abstract][Full Text] [Related]
8. [Procedures and methods of benefit assessments for medicines in Germany].
Bekkering GE; Kleijnen J
Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
[TBL] [Abstract][Full Text] [Related]
9. Decision-making in the midst of uncertainty: appraising expensive medicines in England.
Calnan M
Cien Saude Colet; 2021 Nov; 26(11):5523-5531. PubMed ID: 34852087
[TBL] [Abstract][Full Text] [Related]
10. Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?
Towse A
Br J Clin Pharmacol; 2010 Sep; 70(3):360-6. PubMed ID: 20716236
[TBL] [Abstract][Full Text] [Related]
11. [The National Institute for Clinical Excellence (NICE)].
Rothgang H; Niebuhr D; Wasem J; Gress S
Gesundheitswesen; 2004 May; 66(5):303-10. PubMed ID: 15141350
[TBL] [Abstract][Full Text] [Related]
12. Decision analysis for resource allocation in health care.
Griffin S; Claxton K; Sculpher M
J Health Serv Res Policy; 2008 Oct; 13 Suppl 3():23-30. PubMed ID: 18806189
[TBL] [Abstract][Full Text] [Related]
13. Probabilistic analysis and computationally expensive models: Necessary and required?
Griffin S; Claxton K; Hawkins N; Sculpher M
Value Health; 2006; 9(4):244-52. PubMed ID: 16903994
[TBL] [Abstract][Full Text] [Related]
14. The role of NICE technology appraisal in NHS rationing.
Walker S; Palmer S; Sculpher M
Br Med Bull; 2007; 81-82():51-64. PubMed ID: 17409119
[TBL] [Abstract][Full Text] [Related]
15. The use of probabilistic decision models in technology assessment : the case of total hip replacement.
Briggs A; Sculpher M; Dawson J; Fitzpatrick R; Murray D; Malchau H
Appl Health Econ Health Policy; 2004; 3(2):79-89. PubMed ID: 15702945
[TBL] [Abstract][Full Text] [Related]
16. NICE methodological guidelines and decision making in the National Health Service in England and Wales.
Gafni A; Birch S; ;
Pharmacoeconomics; 2003; 21(3):149-57. PubMed ID: 12558466
[TBL] [Abstract][Full Text] [Related]
17. Development of a transparent interactive decision interrogator to facilitate the decision-making process in health care.
Bujkiewicz S; Jones HE; Lai MC; Cooper NJ; Hawkins N; Squires H; Abrams KR; Spiegelhalter DJ; Sutton AJ
Value Health; 2011; 14(5):768-76. PubMed ID: 21839417
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of the National Institute for Health and Care Excellence Diagnostics Assessment Program Decisions: Incremental Cost-Effectiveness Ratio Thresholds and Decision-Modifying Factors.
Chen G; Peirce V; Marsh W
Value Health; 2020 Oct; 23(10):1300-1306. PubMed ID: 33032773
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of a Stratified National Breast Screening Program in the United Kingdom: An Early Model-Based Cost-Effectiveness Analysis.
Gray E; Donten A; Karssemeijer N; van Gils C; Evans DG; Astley S; Payne K
Value Health; 2017 Sep; 20(8):1100-1109. PubMed ID: 28964442
[TBL] [Abstract][Full Text] [Related]
20. Evolution of a cost-utility model of donepezil for Alzheimer's disease.
Peters JL; Anderson R; Hoyle M; Hyde C
Int J Technol Assess Health Care; 2013 Apr; 29(2):147-54. PubMed ID: 23514698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
